Juventas Therapeutics, Inc.
http://www.juventasinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Juventas Therapeutics, Inc.
Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally
Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.
Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
Path Forward For Viridian’s IGF-1R Antibody In Chronic TED Raises Questions
The US firm’s potential rival to Horizon’s Tepezza, VRDN-001, showed positive signals in a small group of patients with chronic thyroid eye disease in a Phase I/II trial, but its decision to drop one planned dosing regimen from an upcoming pivotal trial has put off some analysts.
Novartis Aims To Fly High In Kidney Disease With Chinook Buy
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AcelleRX Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice